SIRT6 in older dogs: what the reported results show

Longevitytech.fund — supporting longevity research

We are proud of Longevitytech.fund’s support for Genflow’s research into SIRT6 gene therapy. A September 14, 2022 announcement issued by Longevity Tech Fund described Genflow Bio among its first-fund investments. This research investigates a protein involved in maintaining DNA and regulating cells, and asks whether its biology can lead to useful treatments. [2] [7]

SIRT6 is a protein involved in maintaining DNA and regulating cellular processes. There are good scientific reasons to investigate it, including an experiment in which genetically modified mice lived longer. The beagle study asks a different question: can giving an intervention later in life produce useful changes? Its interpretation depends on which changes were measured. This article reflects evidence dated September 22, 2026. [1] [2] [3]

What is shown, and what remains open

• Shown: Genflow reports favorable findings in older dogs, including its primary DNA-methylation age estimate. Separate experiments in mice genetically modified to produce more SIRT6 found longer median lifespan, with different functional effects in males and females. [1] [3]

• Not shown: how large or reliable the canine clock effect is, an extension of the dogs’ complete lifespans, or benefit from SIRT6 gene therapy in humans. The dog announcements do not supply complete numerical results. [1] [4] [5]

• What would change the assessment: results for each dog-treatment group, with uncertainty estimates, meaningful function and survival outcomes, comprehensive safety reporting, and a clear protocol. Human benefit would then require human studies.

What the “centenarian gene” label leaves out

Everyone has a SIRT6 gene. Genflow’s work concerns a particular version, often called centSIRT6, rather than a gene exclusive to unusually long-lived people. A gene variant can be an interesting research lead without explaining why someone reached an exceptional age. [2]

The 2022 human study compared 450 exceptionally long-lived Ashkenazi Jewish participants with 550 controls without a family history of exceptional longevity. The long-lived group was eligible from age 95 and averaged about 100; not every participant was a centenarian. The rare variant was more frequent in that group, but the difference from the study controls was not statistically significant: P = 0.3. The study therefore did not establish that carrying the variant makes someone live to 100. [2]

Laboratory experiments gave a more specific signal. The variant improved selected DNA-repair measures and suppression of certain mobile genetic elements—DNA sequences that can move or copy within the genome. It increased the protein’s ability to carry out one type of chemical reaction while reducing another. Calling it simply a universally “stronger” version of SIRT6 misses that tradeoff. These are cellular findings, not treatment outcomes. [2]

A 2023 correction removed an inadvertently cited paper that had been retracted. The authors stated that the removal did not otherwise change the SIRT6 article’s text or interpretation; the SIRT6 study itself was not retracted. [8]

Lifelong genetics and later treatment also differ. Giving an older animal additional genetic instructions changes the amount, timing, and distribution of a protein. It does not reproduce an exceptionally long-lived person’s entire genetic and life history. Genetic findings can support a treatment hypothesis, but cannot replace testing it.

What the mouse lifespan experiment found

In a separate 2021 experiment, mice genetically engineered to produce more SIRT6 lived longer than their unmodified littermates. Median lifespan—the middle lifespan in each group—increased by 27% in males and 15% in females in that mouse strain. The SIRT6 groups included 51 males and 41 females; control groups included 52 and 50, respectively. Researchers followed the animals to death or humane euthanasia, without excluding mice from the survival analysis. [3]

The functional results were less uniform. Older males maintained better running performance, while several activity tests in older females did not improve. The study also reported metabolic changes. Longer median lifespan therefore coexisted with selective functional effects; the study did not show that every function improved in both sexes. [3]

These mice produced extra SIRT6 because of an inherited genetic modification. They were not aged animals newly receiving Genflow’s centSIRT6 product. The experiment supports the target’s biological plausibility, but does not provide a human dose, a clinical benefit estimate, or safety evidence for a different formulation and delivery system. The dog study asks whether giving genetic instructions later in life can improve outcomes in a larger animal.

What Genflow tested in older beagles

SLAB stands for Sarcopenia and Longevity in Aged Beagles; sarcopenia refers to loss of muscle. Genflow describes a randomized, blinded study of 24 beagles older than 10 years, divided among four groups. Two received different doses of DNA encoding the SIRT6 variant without a viral carrier, often called “naked” DNA. A third received a single administration using an AAV8 viral vector to carry the genetic instructions. The control group received saline. [1] [4]

These delivery methods need separate benefit and safety results. Pooling treated animals may conceal differences between the DNA and viral-vector approaches. The available announcements do not establish the number of dogs in each group. Those numbers and separate results are needed to compare the approaches reliably.

Random assignment to groups and keeping treatment assignments hidden from relevant study personnel reduce some sources of bias. Still, 24 animals across four groups is a small study. Complete information about starting health, missing measurements, withdrawals, and statistical analysis is needed to judge an apparent difference. The announcements leave those details incomplete. [1] [4] [5]

What the three announcements say

These reports document what the sponsor says occurred. A complete scientific report would allow closer assessment of the methods, magnitude, and consistency of those findings. Positive wording alone cannot show whether an effect is substantial or precise.

An age estimate is different from survival or mobility

A DNA-methylation clock combines measurements of chemical marks on DNA into an age estimate. A treatment can change that estimate without demonstrating that an animal stays mobile, avoids illness, or lives longer. A biomarker becomes a useful substitute for a health outcome only when evidence links treatment-induced changes to that outcome in the relevant setting. [6]

The US Food and Drug Administration (FDA) calls these substitutes surrogate endpoints and explains why evidence is needed for each intended use. This requirement is a general principle, not an FDA assessment of Genflow’s canine clock. [6]

Here the clock’s exact identity also needs clarification. The February release used “GrimAge,” while September used “GRIM.” The reports do not resolve whether these labels refer to the same method. The full account needs to identify the clock, sampled tissue, validation in dogs of this age, and analysis planned before the results were known. [1] [4]

Survival asks a more direct question, but requires its own numbers: deaths in each group, timing, reasons for withdrawal or euthanasia, and whether every randomized dog was included. An early survival difference between small groups cannot be judged without those details. Frailty and muscle results likewise need measurement methods and the size of changes; a difference that improves an animal’s daily life carries more practical meaning than an isolated small laboratory shift.

How reassuring is “no adverse events observed”?

It is encouraging within the stated observation period. It is not evidence that a gene therapy has no important risks. The strength of the finding depends on the number exposed to each delivery method, what investigators monitored, how they defined events, and how long follow-up continued. Small studies can miss uncommon or delayed problems. [4] [5]

AAV-delivered instructions and DNA without a viral carrier should not inherit one another’s safety conclusions merely because both concern SIRT6. Any human program would also need product- and route-specific assessment in its intended patient group. The dog observations can inform that work; they cannot complete it.

How Healthy Longevity Clinic experts evaluate the evidence

For a reader interested in remaining strong and independent with age, the useful result would concern function and health over time. HLC therefore separates three questions in SLAB: did a DNA-based age estimate change, did daily function improve meaningfully, and did survival improve over a defined period? Evidence for the first does not automatically answer the other two. [1] [4] [6]

HLC also keeps the research models distinct. The mouse lifespan result deserves attention, including its 27% and 15% median differences and sex-specific functional limits. But a lifelong genetic modification cannot establish the effect of giving a different product to an older dog or person. Likewise, the nonsignificant human variant association does not convert the treatment into a proven “centenarian gene” intervention. [2] [3]

In a clinical conversation, ask which health outcome a proposed treatment is meant to improve and where the evidence for that exact product comes from. For SLAB, complete per-group results could substantially strengthen or weaken the animal case. Repeated improvement in function or survival, together with a clear safety account, would matter more than an unexplained clock label. Human treatment decisions would still need human evidence.

The human program and the next dated milestone

Genflow’s announcements describe GF-1002 as a preclinical candidate and discuss a planned program for metabolic dysfunction-associated steatohepatitis, or MASH, a serious form of fatty liver disease. They do not provide demonstrated human treatment benefit or establish marketing authorization or routine availability for SIRT6 gene therapy. [1] [5]

A future improvement in liver disease could be valuable without demonstrating rejuvenation throughout a healthy person’s body. The patient population, product, route, and intended outcome would determine what such a result means.

Genflow scheduled a detailed presentation for October 2 at the October 1–2, 2026 Animal Longevity Summit in Toronto. That event was still in the future at the September 22 evidence date. A planned presentation is an opportunity to learn more, not a result or a treatment-launch date. The useful next information is the complete dataset, followed by independent replication and, where justified, human trials. [1]

Three questions for a clinical conversation

1. Is the claimed benefit a clock estimate, better everyday function, observed survival, or a human health outcome?

2. Was the evidence obtained with this exact product and delivery method, or with a lifelong genetic modification in mice?

3. What do complete comparison-group results and safety follow-up show beyond the sponsor’s headline?

Common questions

Is SIRT6 a gene only centenarians have?

No. Everyone has SIRT6. The research concerns a particular variant and how SIRT6 activity is changed. The variant’s higher frequency in the selected long-lived group was not statistically significant against the study controls. [2]

Did the beagles live longer?

The sponsor reported better survival during the initial six-month dosing period, without the counts or full survival analysis needed to judge its size and reliability. The September primary endpoint was a clock estimate, not complete lifespan. [1] [4]

Do the mouse lifespan percentages predict human years gained?

No. They describe median lifespan differences in a particular genetically modified mouse strain. They cannot be converted into additional years for people or assigned to Genflow’s later-life gene-therapy product. [3]